Biotech dealmaking has reached its fastest pace in at least seven years, with 38 acquisitions already struck industrywide in 2026 and four of them carrying guaranteed proceeds north of $10 billion apiece. That puts the sector on track to match or exceed the entire mega-deal count from 2025, a year that itself was seen as a strong recovery from the funding drought of 2022 through 2024.

The Numbers Behind the Rebound

The largest deals this year read like a who’s who of pharma consolidation: the Recordati and CVC-GBL consortium transaction, valued at roughly 10.7 billion euros (about $12.4 billion), the Organon and Sun Pharma combination at an enterprise value near $11.75 billion, Merck KGaA’s acquisition of Bio-Techne for approximately $11.3 billion, AbbVie’s purchase of Apogee at roughly $10.9 billion in equity value, and GSK’s acquisition of Nuvalent at about $10.6 billion. Separately, venture investors poured more than $9.1 billion into at least 68 biotech companies between January and June, the strongest first-half venture total since early 2022.

Taken together, the two data sets tell a consistent story. Capital is flowing back into biotech, but it is flowing toward the safest bets: companies with de-risked, late-stage or already-approved assets that a larger acquirer can fold into an existing commercial infrastructure with minimal execution risk.

Who’s Buying and Why

Every one of the five largest deals this year involves a buyer picking up a target with either an approved product, a near-term regulatory catalyst, or a platform that plugs a specific gap in the acquirer’s pipeline. That is a departure from the last true boom cycle, when large pharma companies were more willing to pay up for earlier-stage, higher-risk science on the strength of a single strong data readout.

Bankers advising on these transactions point to two forces pushing buyers toward later-stage assets. First, the patent cliff facing several top-20 pharma companies over the next three to five years has made revenue replacement an urgent, board-level priority, and boards are less willing to bet that urgency on Phase 1 science. Second, the higher cost of capital that has persisted since 2023 makes the long development timelines and binary risk of early-stage biotech a harder sell internally, even when a corporate development team is enthusiastic about the underlying biology.

The Squeeze on Early-Stage Biotech

The flip side of this rebound is a widening gap at the earliest stages of the funding pipeline. Even as headline venture totals recovered in the first half of the year, seed-stage and early platform companies report that the rebound has been uneven, with a disproportionate share of new capital concentrated in a smaller number of larger, later-stage rounds. Emerging therapeutic platforms without a lead asset already in the clinic are finding it harder to raise a first institutional round than at almost any point in the last decade.

That dynamic is pushing more founders and smaller biotechs to look for ways to stretch a smaller check further, and to get a program into human proof-of-concept data as quickly and cheaply as possible, since a clean early readout is now the single best way to attract either a later venture round or an acquirer’s attention before running out of cash.

What It Means for Trial-Stage Companies

That capital-efficiency pressure has real implications for where companies choose to run their first-in-human and early proof-of-concept studies. Sponsors increasingly weigh not just speed to first patient dosed, but the total cost of getting to a readout that can support a subsequent financing or partnership conversation. Jurisdictions that combine fast ethics and regulatory pathways with direct cost offsets have become more attractive by comparison.

Australia is one of the markets benefiting from that shift. The country’s Clinical Trial Notification pathway allows a trial to begin without a pre-existing Investigational New Drug application, often shaving months off study start-up, and the 43.5% R&D Tax Incentive gives eligible overseas sponsors a direct rebate on local trial costs, both increasingly cited by cross-border biotechs evaluating where to generate their first clinical data package.

Looking Ahead to H2

With four mega-deals already on the board and a deep bench of later-stage private companies still looking for an exit, bankers expect the current pace of M&A to hold through the second half of the year, particularly if the Federal Reserve continues on its current rate path. The bigger open question is whether the venture capital that funds tomorrow’s acquisition targets will follow the same late-stage skew, or whether a handful of standout data readouts in the back half of 2026 can pull fresh capital back toward earlier-stage science.